|
Cangene Corporation - Company Profile Snapshot
| Company Profile: |
Cangene Corporation |
| Ticker: |
CNJ |
| Exchanges: |
TOR |
| 2008 Sales: |
166,060,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
CANADA |
| Employees: |
682 |
Business Description
Cangene Corporation. The Group's principal activities are to develop and distribute hyperimmune products and recombinant biopharmaceuticals. Hyperimmune products are specialty antibody preparations made from plasma products. Recombinant protein products are therapeutic proteins made by introducing a particular gene into a host organism, which in turn produces the protein of interest. The Group operates in two segments namely Contract R&D and Manufacturing and Biopharmaceutical Operations. Biopharmaceutical Operations include in-house licensed product sales and royalties and related party research and development. Contract R&D and Manufacturing provides products and services to third party clients. The Group develops and supplies antibody products that may aid in the fight against challenging infectious diseases such as smallpox, Ebola, anthrax, West Nile and hepatitis. The Group markets its products in Canada, the United States and other foreign countries.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
